Q3 2023 Holdings
Filed 2023-11-08 | 53 holdings | $912.8M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Genetron Holdings Ltd | ADS | 37186H100 | $104.6M | 8,124,174 | 11.5% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $94.5M | 3,203,093 | 10.4% |
| Harmony Biosciences Holdings Inc(HRMY) | Common | 413197104 | $85.4M | 2,606,247 | 9.4% |
| Verona Pharma PLC(VRNA) | ADS | 925050106 | $69.3M | 4,249,918 | 7.6% |
| Avadel Pharmaceuticals PLC | ADR | 05337M104 | $42.2M | 4,096,428 | 4.6% |
| Tarsus Pharmaceuticals Inc(TARS) | Common | 87650L103 | $40.2M | 2,262,200 | 4.4% |
| Sinovac Biotech Ltd.(SVA) | SHS | P8696W104 | $38.2M | 5,900,000 | 4.2% |
| Geron Corp(GERN) | Common | 374163103 | $35.0M | 16,524,634 | 3.8% |
| Terns Pharmaceuticals Inc(TERN) | Common | 880881107 | $33.5M | 6,657,992 | 3.7% |
| Gracell Biotechnologies Inc | SPONSORED ADS | 38406L103 | $31.3M | 10,881,144 | 3.4% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $25.7M | 1,678,207 | 2.8% |
| Olema Pharmaceuticals Inc(OLMA) | Common | 68062P106 | $23.1M | 1,873,704 | 2.5% |
| Cogent Biosciences Inc(COGT) | Common | 19240Q201 | $21.9M | 2,244,941 | 2.4% |
| ALX Oncology Holdings Inc(ALXO) | Common | 00166B105 | $20.3M | 4,220,048 | 2.2% |
| Arcellx Inc.(ACLX) | Common | 03940C100 | $18.1M | 503,565 | 2.0% |
| Ventyx Biosciences Inc(VTYX) | Common | 92332V107 | $14.7M | 422,075 | 1.6% |
| Rayzebio Inc | Common | 75525N107 | $14.1M | 633,576 | 1.5% |
| Icosavax, Inc. | Common | 45114M109 | $13.2M | 1,704,568 | 1.4% |
| Astria Therapeutics Inc(CATBUSD) | Common | 04635X102 | $12.5M | 1,681,199 | 1.4% |
| Verastem Inc(VSTM) | Common | 92337C203 | $12.5M | 1,538,461 | 1.4% |
| Compass Pathway PLC(CMPS) | SPONSORED ADS | 20451W101 | $11.9M | 1,608,000 | 1.3% |
| Zai Lab Ltd ADR(ZLAB) | ADR | 98887Q104 | $11.1M | 454,606 | 1.2% |
| Alpine Immune Sciences Inc(NVLSEUR) | Common | 02083G100 | $10.5M | 914,913 | 1.1% |
| Crinetics Pharmaceuticals Inc(CRNX) | Common | 22663K107 | $10.4M | 350,000 | 1.1% |
| Dyne Therapeutics Inc(DYN) | Common | 26818M108 | $9.3M | 1,035,136 | 1.0% |
| IO Biotech Inc(IOBT) | Common | 449778109 | $8.7M | 6,173,439 | 1.0% |
| Apogee Therapeutics Inc(APGE) | Common | 03770N101 | $8.5M | 400,000 | 0.9% |
| KalVista Pharmaceuticals Inc.(KALV) | Common | 483497103 | $8.2M | 856,008 | 0.9% |
| Delcath Systems, Inc.(DCTH) | Common | 24661P807 | $7.5M | 1,855,191 | 0.8% |
| Savara Inc(SVRA) | Common | 805111101 | $7.2M | 1,913,349 | 0.8% |
| Compass Therapeutics Inc(CMPX) | Common | 20454B104 | $7.0M | 3,556,023 | 0.8% |
| Allakos Inc(ALLKGUSD) | Common | 01671P100 | $6.8M | 2,988,000 | 0.7% |
| Aadi Bioscience Inc(WHWK) | Common | 00032Q104 | $6.5M | 509,572 | 0.7% |
| Aclaris Therapeutics, Inc.(ACRS) | Common | 00461U105 | $6.2M | 898,631 | 0.7% |
| Instil Bio Inc | Common | 45783C101 | $5.3M | 12,486,787 | 0.6% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $4.7M | 777,944 | 0.5% |
| Bolt Therapeutics Inc(BOLT1EUR) | Common | 097702104 | $4.0M | 3,871,291 | 0.4% |
| Arrowhead Pharmaceuticals Inc(ARWR) | Common | 04280A100 | $3.7M | 137,411 | 0.4% |
| DBV Technologies SA | Sponsored ADR | 23306J101 | $3.7M | 2,708,875 | 0.4% |
| Sera Prognostics Inc(SERA) | Common | 81749D107 | $3.5M | 1,856,011 | 0.4% |
| Unicycive Therapeutics | Common | 90466Y103 | $3.0M | 3,470,152 | 0.3% |
| Iovance Biotherapeutics Inc(IOVA) | Common | 462260100 | $3.0M | 655,057 | 0.3% |
| Aligos Therapeutics Inc | Common | 01626L105 | $2.6M | 3,547,030 | 0.3% |
| Fulcrum Therapeutics Inc(FULC) | Common | 359616109 | $2.3M | 520,000 | 0.3% |
| Clene Inc(CLNNEUR) | Common | 185634102 | $1.4M | 2,645,338 | 0.2% |
| Impel NeuroPharma Inc | Common | 45258K109 | $1.2M | 2,884,789 | 0.1% |
| Aslan Pharmaceuticals Ltd | ADS | 04522R101 | $1.1M | 568,182 | 0.1% |
| BioAtla Inc(BCAB) | Common | 09077B104 | $908.1K | 534,181 | 0.1% |
| Codexis, Inc(CDXS) | Common | 192005106 | $733.6K | 388,144 | 0.1% |
| Rezolute Inc(RZLT) | Common | 76200L309 | $639.5K | 484,439 | 0.1% |